Prestige Consumer Healthcare (NYSE:PBH) FY Conference Summary Company Overview - **Company**: Prestige Consumer Healthcare - **Date**: January 13, 2026 - **Key Speakers**: CEO Ron Lombardi, CFO Chris Sacco, VP of IR and Treasury Phil Terpolilli Industry Context - The year 2025 was marked by significant external events including a new administration, tariffs, and government shutdowns, impacting consumer behavior and purchasing decisions [2][2] - The healthcare products industry remains resilient as consumers prioritize health-related purchases regardless of economic conditions [2][2] Core Business Insights - **Product Portfolio**: Prestige Consumer Healthcare offers a diverse range of health products, which are essential for treating illnesses, positioning the company well during economic fluctuations [2][2] - **Brand Strategy**: The company focuses on building and growing product categories through innovation rather than merely competing for market share [4][4] - **Innovation Examples**: The introduction of non-drowsy Dramamine and ginger chews for nausea exemplifies the company's strategy to expand product offerings and cater to consumer needs [6][7] Financial Performance - **Gross Margin Impact**: The company faced challenges with gross margins due to tariffs and disruptions in the eye care business, with tariffs costing approximately $5 million in fiscal 2026 [19][19] - **EBITDA Margin**: The company maintains a strong EBITDA margin of 33%-34%, indicating robust profitability despite margin pressures [21][21] Distribution Channels - The company has a broad distribution strategy, successfully adapting to consumer shopping preferences, particularly with growth in mass retail and e-commerce channels [13][14] - The Amazon business continues to grow at double-digit rates, while traditional drug and regional grocery channels are experiencing declines [14][14] M&A and Capital Allocation Strategy - **M&A Focus**: The company is actively seeking acquisition opportunities in the fragmented consumer healthcare market, with a disciplined approach to evaluating potential brands [25][29] - **Capital Allocation**: The company plans to balance M&A, share repurchases, and cash build, expecting to generate $1 billion in free cash flow over the next four years [26][26] International Business - The international segment has been performing well, contributing over 10% of total revenue, with brands like Hydralite and FESS showing strong growth [32][32] Private Label Competition - The company acknowledges the presence of private label products but emphasizes its focus on niche brands with strong consumer trust, which helps mitigate the impact of private label competition [37][38] Women's Health Segment - Brands like Monistat and Summer's Eve are positioned for growth, with Monistat achieving a market share of approximately 55% [41][41][42] Conclusion - Prestige Consumer Healthcare is well-positioned for future growth through a diversified product portfolio, strong brand strategies, and a proactive approach to market changes and consumer needs. The company remains focused on innovation and strategic acquisitions to enhance its market presence and profitability.

Core Insights - Heartland Advisors reported a strong performance for small-cap stocks in Q3 2025, with the Russell 2000® Index increasing by 12.39%, outperforming the S&P 500 Index's 8.12% rise [1] - The Heartland Value Plus Fund returned 8.51% in Q3 2025, lagging behind the Russell 2000® Value Index, which gained 12.60% [1] Company-Specific Insights - Prestige Consumer Healthcare Inc. (NYSE:PBH) was highlighted as a significant detractor in the Heartland Value Plus Fund's performance due to missed earnings forecasts and lowered EPS estimates related to supply chain issues in its eye care segment [3] - The stock of Prestige Consumer Healthcare Inc. experienced a one-month return of -3.13% and a 52-week decline of 12.96%, closing at $61.00 per share with a market capitalization of $3.002 billion on October 10, 2025 [2] - In Q1 2026, Prestige Consumer Healthcare Inc. reported revenue of $249.5 million, down from $267.1 million in the previous year, indicating potential challenges in maintaining revenue growth [4] Hedge Fund Interest - Prestige Consumer Healthcare Inc. was held by 19 hedge fund portfolios at the end of Q2 2025, a decrease from 23 in the previous quarter, suggesting a decline in interest among hedge funds [4]

Prestige Consumer Healthcare Conference Summary Company Overview - Prestige Consumer Healthcare Inc. (NYSE: PBH) is a consumer healthcare company focused on over-the-counter medicines, helping consumers care for themselves daily [2][3] Key Business Segments - The company has a diversified portfolio of brands, including: - Monistat (50%+ market share in vaginal antifungal treatment) - Summer's Eve (40%+ market share in feminine hygiene) - Dramamine (60% market share in motion sickness) [4][5][10] Financial Performance - Over the last five years, total revenue grew by approximately 3.5%, with organic revenue growth in the range of 2% to 3% [9] - Adjusted earnings increased by about 9% annually, exceeding the long-term target of 6% to 8% [9] - The company maintains best-in-class EBITDA margins in the low 30s, contributing to strong free cash flow generation [7][22] Growth Strategy - The growth strategy is built on three pillars: 1. Investing in brand building to achieve 2% to 3% organic growth [6] 2. Maintaining a strong financial profile with an asset-light model and high free cash flow [7] 3. Reinvesting free cash flow into capital allocation for further growth and potential acquisitions [8][22] E-commerce Growth - E-commerce sales have increased from less than 1% to over 16% of total sales in the last five years, driven by investments in content and marketing [15][16] - The company aims to be channel-agnostic, ensuring products are available across various platforms [40] Innovation and Brand Building - The company introduces 3 to 5 new products annually, focusing on incremental innovations rather than large-scale launches [17] - Recent innovations include expanding the Dramamine brand to include non-drowsy options and nausea relief products [11][12] - The introduction of a maintain subline for Monistat allows for broader usage beyond acute treatment [19] International Expansion - The international segment accounts for about 16% of sales, with expected growth rates exceeding 5% [20] - Key brands include Hydralyte, a leading rehydration product in Australia, with plans for geographic expansion [20][21] Capital Allocation Strategy - The company prioritizes: 1. Investing in current brands for organic growth 2. M&A opportunities to consolidate consumer healthcare brands 3. Strategic share repurchases to offset dilution [23][24] - The company has a long-term leverage target of less than 3 times, currently at 2.4x [22] Challenges and Future Outlook - The Clear Eyes brand faced supply chain challenges, leading to a shortfall in revenue. The company is acquiring a critical supplier to enhance production capacity [26][32] - The long-term outlook remains positive, with expectations for continued free cash flow generation and strategic capital allocation to enhance shareholder value [26][27] Conclusion - Prestige Consumer Healthcare is well-positioned for sustainable growth through a diversified brand portfolio, strong financial management, and a focus on innovation and market expansion [27]

Financial Data and Key Metrics Changes - The company reported a free cash flow of approximately $242 million for the previous year, with an outlook for this year exceeding $245 million [10][48] - The five-year compound annual growth rates (CAGRs) showed revenue growth of about 3.5%, organic growth of 2.5%, and earnings per share (EPS) growth of nearly 9% [12] Business Line Data and Key Metrics Changes - The largest category for the company is gastrointestinal (GI) health, followed by women's health, eye and ear care, skin care, and analgesics [4] - The company has a diverse portfolio that allows it to manage fluctuations in illness levels effectively, with brands performing variably based on market conditions [6][51] Market Data and Key Metrics Changes - The company's e-commerce sales have grown significantly, increasing from about 4% of total sales five years ago to approximately 16% at the end of the last fiscal year, with two-thirds of that coming from Amazon [25] - The international business, particularly in Australia, has been growing in the mid-teens on average over the last five years, exceeding long-term expectations [37] Company Strategy and Development Direction - The company focuses on niche categories where brands can compete successfully over the long term, emphasizing brand building and consumer insights [2][8] - The management plans to utilize free cash flow for mergers and acquisitions (M&A), share repurchases, and maintaining a strong balance sheet [41][42] Management's Comments on Operating Environment and Future Outlook - Management acknowledged capacity constraints affecting the Clear Eyes brand but expressed confidence in addressing these issues with new suppliers coming online [47][48] - The company maintains its free cash flow outlook despite adjustments to top-line expectations, indicating resilience in its business model [48] Other Important Information - The company has a strong financial profile characterized by low capital expenditures and a variable cost model, which supports consistent free cash flow generation [40] - The management highlighted the importance of consumer insights in driving product innovation and brand growth [53] Q&A Session Summary Question: What are the kind of valuations the company is seeing? - The company has not observed a meaningful shift in valuations for the brands it targets, emphasizing its competitive advantages over private equity in terms of cost of capital and operational sophistication [59] Question: How does the company view the shift in retail channels? - Management noted that channel shifts are not new and emphasized the importance of adapting marketing strategies to support retail partners across various channels, including drugstores and e-commerce [61][62]

Financial Data and Key Metrics Changes - The company reported a free cash flow of approximately $242 million for the previous year, with an outlook of over $245 million for the current year, indicating a strong financial profile and consistent cash generation [9][48]. - The five-year compound annual growth rates (CAGRs) showed revenue growth of about 3.5%, organic growth of 2.5%, and earnings per share (EPS) growth of nearly 9% [11]. Business Line Data and Key Metrics Changes - The company operates in several categories, with gastrointestinal (GI) being the largest, followed by women's health, eye and ear care, skin care, and analgesics [4][5]. - The company has a diverse portfolio that allows it to manage fluctuations in illness levels effectively, with brands performing variably based on market conditions [6][10]. Market Data and Key Metrics Changes - The e-commerce segment has grown significantly, with online sales increasing from about 4% of total sales five years ago to approximately 16% by the end of the last fiscal year, with two-thirds of that attributed to Amazon [24][25]. - The international business, particularly in Australia, has been growing in the mid-teens, exceeding long-term expectations of mid to high single-digit growth [36]. Company Strategy and Development Direction - The company focuses on investing in niche categories where brands can compete effectively, emphasizing a brand-building playbook that includes understanding consumer insights and agile marketing strategies [2][12]. - The company aims to utilize its strong cash flow for mergers and acquisitions (M&A), share repurchases, and maintaining a low leverage ratio, with a preference for M&A as the primary use of cash [41][42]. Management's Comments on Operating Environment and Future Outlook - Management acknowledged capacity constraints affecting certain brands but expressed confidence in addressing these issues through new supplier agreements and operational adjustments [46][48]. - The company maintains its free cash flow outlook despite adjustments to top-line revenue expectations, indicating resilience in its financial performance [48]. Other Important Information - The company has a disciplined approach to M&A, focusing on acquiring brands with leading positions in niche categories, and has significant acquisition capacity without returning to previous high leverage levels [44][45]. - The company has successfully launched several new products, including Dramamine advanced herbals for kids and Summer's Eve whole body deodorant, which have performed well in their respective markets [31][33]. Q&A Session Summary Question: What are the kind of valuations the company is seeing in the market? - The company has not observed a meaningful shift in valuations for the types of brands it seeks, emphasizing its competitive advantages over private equity in terms of cost of capital and operational sophistication [58][59]. Question: How does the company view the shift in retail channels from traditional drugstores to clubs and retailers? - The company has adapted to channel shifts by developing unique programs for each retail partner and remains committed to supporting brands in the drug channel while also leveraging opportunities in e-commerce and other retail formats [60][62].

Financial Performance & Strategy - FY25 revenues reached $1,137.8 million[69] - The company achieved a 5-year revenue CAGR of 34%[17,69] - Adjusted EPS 5-year CAGR was +88%[17] - Organic revenue 5-year CAGR was +24%[17,69] - Adjusted FY25 Free Cash Flow reached $243291 thousand[49,75] - Net leverage was significantly reduced to 24x[49] - The company anticipates approximately $1 billion total Free Cash Flow over the next four years[51] E-commerce & International Expansion - E-commerce as a percentage of net sales has increased +4x from approximately 4% in FY19 to approximately 16% in FY25[33] - International revenue accounts for approximately 16% of Prestige Net Sales in FY25[45] FY26 Outlook - Expected revenue for FY26 is projected to be between $1,100 to $1,115 million[59] - Projected FY26 Non-GAAP Free Cash Flow is $245 million[59,77]

Financial Data and Key Metrics Changes - Q1 sales were approximately $250 million, which was below the forecast of $258 million to $260 million, representing a year-over-year decline largely due to supply chain issues in eye care [6][12] - Gross margin expanded by 150 basis points to 56.2%, attributed to ongoing cost savings efforts [8][12] - Diluted EPS was $0.95, up approximately 6% compared to the adjusted prior year, despite the sales miss [9][16] - Free cash flow reached a quarterly record of $78 million, enabling capital deployment to enhance shareholder value [9][17] Business Line Data and Key Metrics Changes - North America segment revenues decreased by 8.4%, while International segment revenues increased by 7.1% year-over-year [13] - The International segment experienced organic sales growth of 7%, driven by broad-based sales growth [14] Market Data and Key Metrics Changes - The company anticipates a full-year revenue of $1.1 billion to $1.115 billion, with organic revenue expected to decline approximately 1.5% to 3% [22] - For Q2, revenues are expected to be approximately $256 million to $259 million, down year-over-year due to supply chain timing and lower retail order patterns [22] Company Strategy and Development Direction - The company announced the acquisition of Pillar Five to secure and expand long-term supply for eye care products, which is expected to improve supply stability in the second half of the year [11][19] - The company maintains confidence in its diverse consumer healthcare portfolio and long-term growth opportunities despite the disappointing start to the year [21] Management Comments on Operating Environment and Future Outlook - Management highlighted heightened business environment uncertainty due to supply chain constraints, high inflation, and geopolitical events [5] - The company expects significant improvement in Clear Eye shipments in the second half of the year, with a focus on recovering lost sales in FY 2027 and beyond [22][29] Other Important Information - The anticipated cost of tariffs for the full year is approximately $5 million, which the company expects to offset through strategic actions [15] - The acquisition of Pillar Five is expected to be funded from cash on hand and will have a minimal impact on the P&L, being approximately neutral to EPS on a normalized basis [19][63] Q&A Session Summary Question: Change in retail order patterns and inventory destocking - Management noted increased order volatility from retailers in July, which is expected to significantly impact Q2 but anticipates a return to normalized order trends in the second half [25][26] Question: Confidence in Clear Eyes supply normalizing - Management expressed confidence in supply normalizing in the back half of the year, with expectations of recovering lost sales in FY 2027 and beyond [29][30] Question: Impact of bringing eye care manufacturing in-house on margins - Management does not expect any meaningful movement in gross margin as a result of the acquisition of Pillar Five, indicating it will be largely neutral to the P&L [37][38] Question: Inventory levels and destocking expectations - Management does not see any meaningful ramp-up of inventory among their largest customers, indicating that inventory levels are not inflated [45][46] Question: Performance of the women's health business - Management remains optimistic about the continued recovery of the Summer's Eve brand, expecting positive performance for the remainder of the year [48] Question: Sustaining international growth - Management is confident in sustaining international growth, expecting a slight softening compared to the first quarter but still in line with long-term growth algorithms [70]

Financial Data and Key Metrics Changes - Q1 sales were approximately $250 million, which was below the forecast of $258 million to $260 million, representing a year-over-year decline largely due to supply chain issues and lower sales in eye care [5][10] - Gross margin expanded by 150 basis points to 56.2%, attributed to cost savings efforts [6][12] - Diluted EPS was $0.95, up approximately 6% from the adjusted prior year, despite the sales miss [7][14] - Free cash flow reached a record $78 million, enabling capital deployment for shareholder value enhancement [7][15] Business Line Data and Key Metrics Changes - North America segment revenues decreased by 8.4%, while International segment revenues increased by 7.1% year-over-year [11][12] - The eye care segment faced significant supply constraints, impacting sales, while other segments like Dramamine and Fleet showed healthy consumption trends [6][12] Market Data and Key Metrics Changes - The International segment experienced organic sales growth of 7%, driven by broad-based sales growth [12] - E-commerce channel saw double-digit year-over-year consumption growth, indicating a long-term trend towards higher online purchasing [12] Company Strategy and Development Direction - The company announced the acquisition of Pillar Five to secure and expand long-term supply for eye care products, which is expected to improve supply stability in the second half of the year [9][17] - The company anticipates revenues for fiscal 2026 to be between $1.1 billion and $1.115 billion, with organic revenue expected to decline approximately 1.5% to 3% [20] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment in the start of the year but remains confident in the long-term growth opportunities of their consumer healthcare portfolio [19] - The company expects significant improvement in Clear Eye shipments in the second half of the year, despite current supply chain challenges [20][29] Other Important Information - The company maintained a leverage ratio of approximately 2.4 times and repurchased over 400,000 shares in Q1 [7][15] - The anticipated cost of tariffs for the full year is approximately $5 million, which the company expects to offset through strategic actions [13] Q&A Session Summary Question: Change in retail order patterns and inventory destocking - Management noted increased order volatility from retailers in July, disconnected from consistent consumption levels, impacting Q2 significantly [23][24] Question: Confidence in supply normalizing for Clear Eyes - Management expressed confidence in supply normalizing in the back half of the year, with new suppliers and a high-speed line expected to contribute [26][29] Question: Impact of bringing eye care manufacturing in-house on margins - Management indicated no meaningful movement in gross margin as a result of bringing manufacturing in-house, expecting it to be largely neutral to the P&L [36][39] Question: Outlook for cough and cold season - Management maintained the initial guidance for a modest decline in the cough and cold category, too early to tell at this point [42] Question: Inventory levels within segments - Management reported no meaningful ramp-up of inventory, indicating that current order patterns are disconnected from consumption [44] Question: Performance of Summer's Eve brand - Management expressed confidence in the continued positive momentum of the Summer's Eve brand for the remainder of the year [46] Question: International segment growth sustainability - Management expects to sustain international growth, projecting a long-term algorithm of over 5% for the segment [68]

Prestige Consumer Healthcare (PBH) FY Conference Summary Company Overview - Prestige Consumer Healthcare sells and distributes over-the-counter health care products in the US, Canada, and certain international markets, with well-known brands like Dramamine, Clear Eyes, Dentech, and Ludens [2][4] Core Strategy and Financial Performance - The company's strategy focuses on building a consumer health care portfolio with leading brands in niche categories, which has remained unchanged over time [4][5] - Fiscal year 2025 ended with record sales and earnings per share (EPS), alongside significant cash flow performance, resulting in the lowest leverage in the company's history [7] - The company anticipates generating approximately $1 billion in free cash flow over the next four years [7][54] Consumer Behavior and Market Dynamics - Consumers are becoming more thoughtful in their shopping habits, seeking better value propositions without switching to different products [9][10] - There have been no significant changes in the competitive landscape, with no new entrants affecting the categories in which Prestige competes [12][13] Tariffs and Pricing Strategy - The company expects a cost impact of approximately $15 million for fiscal year 2026 due to tariffs, with a total annualized impact of around $20 million [16] - Prestige is well-positioned to navigate the tariff environment due to a diverse portfolio and a largely domestic supply base [19][20] Product Portfolio Insights - Clear Eyes is expected to recover from supply chain challenges over the next couple of years, with efforts to expand capacity and bring on new suppliers [24][25] - Women's health products, particularly Monistat and Summer's Eve, are showing signs of recovery, with Monistat stabilizing and Summer's Eve experiencing year-over-year sales growth for the first time in three years [28][30] - The international segment is projected to grow in the mid-single digits, driven by strong brand performance in Australia and surrounding regions [31][33] E-commerce and Marketing Strategy - E-commerce has been growing at over 10% annually, with a focus on leveraging online platforms as marketing tools to connect with new shoppers [34][36] Financial Outlook and Growth Targets - The company targets 2% to 3% organic sales growth and 6% to 8% EPS growth in the long term, supported by a diverse portfolio and stable profit margins [46][48] - Gross margin is expected to improve to approximately 56.5% for fiscal year 2026, with ongoing cost-saving initiatives [51][52] Capital Allocation and M&A Strategy - Capital allocation priorities include organic growth investments, M&A opportunities, and share repurchases, with a focus on maintaining leverage below three times [54][56] - The company continues to see consistent M&A opportunities, particularly in the consumer health care space, with a preference for acquisitions in the $200 million to $500 million range [62][65] Conclusion - Prestige Consumer Healthcare is well-positioned for long-term growth, with a strong portfolio, effective strategies to navigate market challenges, and a clear focus on capital allocation and M&A opportunities [66]

Financial Performance & Growth - Prestige Consumer Healthcare's revenue has a 5-year Compound Annual Growth Rate (CAGR) of +3.4%[17] - The company's Adjusted Earnings Per Share (EPS) has a 5-year CAGR of +8.8%[17] - Organic revenue has a 5-year CAGR of +2.4%[17] - The company anticipates approximately $1 billion total Free Cash Flow over the next four years[49] E-commerce & International Expansion - E-commerce as a percentage of net sales has increased +4x from approximately 4% in FY19 to approximately 16% in FY25[33] - International revenue accounts for approximately 16% of Prestige Net Sales in FY25[43] Capital Allocation & Debt - The company's Net Leverage has decreased from 4.2x in FY21 to 2.4x in FY25[47] - The company had $52 million in share repurchases[47] Revenue Breakdown by Category (FY25) - Feminine Hygiene accounts for 23% of FY25 revenues[13] - Vaginal Anti-Fungal accounts for 21% of FY25 revenues[13] - Wart Removal accounts for 16% of FY25 revenues[13] - Lice/Parasite Treatment accounts for 11% of FY25 revenues[13]